Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3838319 | 1.00 | LMNA (0.38) | LMNAACE2 | |
| SCHEMBL4806963 | 1.00 | LMNA (0.38) | LMNAACE2 | |
| SCHEMBL11324250 | 1.00 | LMNA (0.38) | LMNAACE2 | |
| SCHEMBL5076457 | 1.00 | LMNA (0.38) | LMNAACE2 | |
| SCHEMBL17219813 | 1.00 | LMNA (0.38) | LMNAACE2 | |
| SCHEMBL453968 | 1.00 | LMNA (0.38) | LMNAACE2 | |
| SCHEMBL2461382 | 1.00 | LMNA (0.38) | LMNAACE2 | |
| SCHEMBL5792782 | 1.00 | LMNA (0.38) | LMNAACE2 | |
| SCHEMBL2418061 | 1.00 | LMNA (0.38) | LMNAACE2 | |
| SCHEMBL6764066 | 1.00 | LMNA (0.38) | LMNAACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190214577-A1 | THERMALLY ACTIVATED DELAYED FLUORESCENCE MATERIAL, POLYMER, MIXTURE, FORMULATION, AND ORGANIC ELECTRONIC DEVICE | GUANGZHOU CHINARAY OPTOELECTRONIC MATERIALS LTD. (CN) | 2019-07-11 | — | — | US | claimed |
| US-9399030-B2 | Topically applied circulation enhancing agent and skin and hair cosmetic and bath agent containing the same | AJINOMOTO CO., INC. (JP) | 2016-07-26 | — | — | US | claimed |
| EP-1853547-B1 | PRODUCTION METHOD OF CAPSINOID BY DEHYDRATING CONDENSATION AND STABILIZING METHOD OF CAPSINOID | AJINOMOTO KK (JP) | 2014-11-12 | — | — | EP | claimed |
| CN-101137613-B | Method for producing capsinoid by dehydration condensation, method for stabilizing capsinoid, and capsinoid composition | AJINOMOTO KK | 2012-03-28 | — | — | CN | claimed |
| US-20100152291-A1 | PRODUCTION METHOD OF CAPSINOID BY DEHYDRATING CONDENSATION, STABILIZING METHOD OF CAPSINOID, AND CAPSINOID COMPOSITION | AJINOMOTO CO., INC. (JP) | 2010-06-17 | — | — | US | claimed |
| EP-1423137-B1 | LIPOPEPTIDE STEREOISOMERS, METHODS FOR PREPARING SAME, AND USEFUL INTERMEDIATES | CUBIST PHARM INC (US) | 2009-04-29 | — | — | EP | claimed |
| CN-101137613-A | Method for producing capsinoid by dehydration condensation, method for stabilizing capsinoid, and capsinoid composition | AJINOMOTO KK (JP) | 2008-03-05 | — | — | CN | claimed |
| EP-1853547-A1 | PRODUCTION METHOD OF CAPSINOID BY DEHYDRATING CONDENSATION, STABILIZING METHOD OF CAPSINOID, AND CAPSINOID COMPOSITION | Ajinomoto Co., Inc. (JP) | 2007-11-14 | — | — | EP | claimed |
| US-20070020738-A1 | produced in a high yield in a short time using an enzyme; capsinoid can be stably preserved by coexistence of a fatty acid; enables industrially production | AJINOMOTO CO., INC (JP) | 2007-01-25 | — | — | US | claimed |
| US-20060287390-A1 | Topically applied circulation enhancing agent and skin and hair cosmetic and bath agent containing the same | AJINOMOTO CO., INC. (JP) | 2006-12-21 | — | — | US | claimed |
| WO-2006088239-A1 | PRODUCTION METHOD OF CAPSINOID BY DEHYDRATING CONDENSATION, STABILIZING METHOD OF CAPSINOID, AND CAPSINOID COMPOSITION | AJINOMOTO CO., INC. (JP) | 2006-08-24 | — | — | WO | claimed |
| EP-1423137-A4 | LIPOPEPTIDE STEREOISOMERS, METHODS FOR PREPARING SAME, AND USEFUL INTERMEDIATES | CUBIST PHARM INC (US) | 2005-11-30 | — | — | EP | claimed |
| EP-1423137-A2 | LIPOPEPTIDE STEREOISOMERS, METHODS FOR PREPARING SAME, AND USEFUL INTERMEDIATES | Cubist Pharmaceuticals, Inc. (US) | 2004-06-02 | — | — | EP | claimed |
| US-20030096948-A1 | Lipopeptide stereoisomers, methods for preparing same, and useful intermediates | ADOLOR CORPORATION | 2003-05-22 | — | — | US | claimed |
| WO-2003017924-A2 | LIPOPEPTIDE STEREOISOMERS, METHODS FOR PREPARING SAME, AND USEFUL INTERMEDIATES | CUBIST PHARMACEUTICALS, INC. (US) | 2003-03-06 | — | — | WO | claimed |
| WO-2024147345-A1 | COATED NEGATIVE ELECTRODE ACTIVE MATERIAL PARTICLES FOR LITHIUM ION BATTERIES, NEGATIVE ELECTRODE FOR LITHIUM ION BATTERIES, LITHIUM ION BATTERY, AND METHOD FOR PRODUCING COATED NEGATIVE ELECTRODE ACTIVE MATERIAL PARTICLES FOR LITHIUM ION BATTERIES | ＡＰＢ株式会社 | 2024-07-11 | — | — | WO | disclosed |
| EP-3808792-B1 | AQUEOUS EMULSION OF POLYETHER HAVING AT LEAST ONE REACTIVE SILYL GROUP | KANEKA BELGIUM NV (BE) | 2024-07-03 | — | — | EP | disclosed |
| EP-0306919-A2 | Liquid crystalline compounds and process for production thereof | DAISO CO., LTD. (JP) | 1989-03-15 | — | — | EP | disclosed |
| EP-0269963-A2 | Ferroelectric liquid crystals | F. HOFFMANN-LA ROCHE AG (CH) | 1988-06-08 | — | — | EP | disclosed |
| EP-0268198-A2 | Ferroelectric liquid crystals | F. HOFFMANN-LA ROCHE AG (CH) | 1988-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287390-A1 | Topically applied circulation enhancing agent and skin and hair cosmetic and bath agent containing the same | CUTA, VEGFA, LIPG | LMNA 3283/4885ACE2 2985/4885 |
| US-20030096948-A1 | Lipopeptide stereoisomers, methods for preparing same, and useful intermediates | LSS, NGLY1, RPN1 | LMNA 589/4885ACE2 2844/4885 |
| US-20190214577-A1 | THERMALLY ACTIVATED DELAYED FLUORESCENCE MATERIAL, POLYMER, MIXTURE, FORMULATION, AND ORGANIC ELECTRONIC DEVICE | TEAD2, TEAD3, TEAD1 | LMNA 1659/4885ACE2 3132/4885 |
| US-20100152291-A1 | PRODUCTION METHOD OF CAPSINOID BY DEHYDRATING CONDENSATION, STABILIZING METHOD OF CAPSINOID, AND CAPSINOID COMPOSITION | FADS2, FADS1, FASN | LMNA 1859/4885ACE2 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.